Answers are grounded in this paper and cite their sources.
The tumor microenvironment (TME) is a dynamic ecosystem that actively shapes cancer progression, therapeutic resistance, and immune escape. It comprises malignant cells, stromal and endothelial cells, extracellular matrix components, and infiltrating immune populations with both pro- and anti-tumor functions. While immune surveillance can eliminate transformed cells early in tumorigenesis, established malignancies undergo immunological and metabolic reprogramming that enables immune evasion and a durable suppressive niche, defined by accumulation of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), regulatory B cells (Bregs) and tolerogenic dendritic cells (DCs). These populations inhibit cytotoxic T lymphocytes and natural killer cells via inhibitory cytokines, checkpoint engagement, metabolic competition, nutrient depletion, and immunosuppressive metabolites. Beyond classical regulatory signaling, metabolic remodeling is a central driver of immune suppression. Enhanced glycolysis and mitochondrial reprogramming in cancer cells cause nutrient depletion, hypoxia, and acidification, impairing immune-cell differentiation and function. Suppressive populations adapt by preferentially using oxidative phosphorylation, fatty acid oxidation, amino acid metabolism, and tumor-derived metabolites such as lactate, adenosine, and kynurenine, actively reinforcing immunosuppression. Lactate also signals to drive regulatory immune-cell differentiation, while tryptophan catabolism and adenosine signaling act as metabolic immune checkpoints that suppress effector lymphocytes. This review synthesizes the cellular and metabolic architecture of the immunosuppressive TME, highlighting bidirectional interactions between metabolic stress and immune dysfunction that drive tumor progression and therapy resistance, and discusses emerging therapeutic strategies targeting immunometabolic pathways, including reprogramming of suppressive populations and combination approaches pairing metabolic interventions with checkpoint blockade and adoptive cellular therapies.
No takes yet. Share an insight, caveat, or question.
Baxevanis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: